This study is accepting new patients by invitation only
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedstudy ends around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ionis Pharmaceuticals, Inc.
- ID
- NCT05667493
- Phase
- Phase 3 Cardiomyopathy Research Study
- Study Type
- Interventional
- Participants
- Expecting 1400 study participants
- Last Updated